Effects of rhDNAase on lung function and nutritional status in a cystic fibrosis pediatric population;Effets de la rhDNase sur la fonction respiratoire et le statut nutritionnel de l'enfant et de l'adolescent atteints de mucoviscidose

Archives de Pediatrie

Volumn 5, Issue 4, 1998, Pages 378-383

  Wizla Derambure, N ^a   Michaud, L ^a   Sardet, A ^a   Deschildre, A ^a   Loeuille G A ^a   Tassin, E ^a   Loire, N ^a   Buisine, C ^a   Boutry, E ^a   Dias, J ^a   Hecquet, F ^a   Turck, D ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Child; Cystic fibrosis; Dornase alfa; Expectorants; Lung volume measurements; Nutritional status; Recombinant proteins

Indexed keywords

DORNASE ALFA; DEOXYRIBONUCLEASE I; DNASE1 PROTEIN, HUMAN; EXPECTORANT AGENT; RECOMBINANT PROTEIN;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; DRUG EFFECT; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SPIROMETRY; VITAL CAPACITY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; EXPECTORANTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; NUTRITIONAL STATUS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SPIROMETRY; VITAL CAPACITY;

EID: 0032034240     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(98)80023-7     Document Type: Article

References (13)

1. 1 Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993 ; 342 : 199-202
2. 2 Bryson HM, Sorkin EM. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 1994 ; 48 : 894-906
3. 3 Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symtoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994 ; 331 : 637-42
4. 4 Dias J, Hecquet F. Expérience lilloise de l'utilisation de la rhDNase chez l'enfant et l'adolescent atteint de mucoviscidose (À propos de 69 patients) [Thèse]. Lille, France : Université de Lille II, 1997
5. 5 Ramsey BW, Astly SJ, Aitken ML, Burke W, Colin AA, Dorkin HL et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993 ; 148 : 145-51
6. 6 Duhamel JF, Laurans M, De Schrevel G, Brouard J. Expérience normande du traitement par rhDNase dans la mucoviscidose. Arch Pédiatr 1996 ; 3: 403S
7. 7 Deneuville E, Dabadie A, Dassonville J, Donnio PY, Desrues B, Roussey M. Traitement par la rhDNase. Expérience du CHR de Rennes. Arch Pédiatr 1996 ; 3 : 373S
8. 8 Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996 ; 153 : 752-60
9. 9 Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995 ; 89 : 499-502
10. 10 Hodson ME, Shah PL. DNase trials in cystic fibrosis. Eur Resp J 1995 ; 8 : 1786-91
11. 11 Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997 ; 23 : 243-8
12. 12 Danner I, Baro-Puigdemasa I, Escande D. Pharmacologie des canaux ioniques dans la mucoviscidose. Bases physiologiques et applications thérapeutiques. Rev Pneumol Clin 1995 ; 51 : 186-92
13. 13 Iatcheva E, Boule M, Baculard A, Delaisi B, Fauroux B, Tournier G et al. Treatment by rhDNase (Pulmozyme®) in paediatric patients: retrospective study. Israël J Med Sci 1996 ; 32 : S224